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1. Value of the data {#s0005}
====================

--Up to date, no prospective data on the power of the adipokine omentin to predict cardiovascular events are available.--The data from our prospective cohort study for the first time shows that elevated plasma omentin significantly predicts cardiovascular events.--This data are important, because the limited existing literature on omentin had rather suggested benefits on cardiometabolic parameters in other populations.--The adipokine omentin may serve as a potential new biomarker in coronary patients.--The data may stimulate future research addressing omentin in different patient cohorts.

2. Data {#s0010}
=======

The data presented here show the incidence of cardiovascular events and study endpoints (EP) respectively in 295 coronary patients according to their plasma omentin concentration. Patients were separated into a group with high (above the median, *n*=147) and low (below the median, *n*=148) omentin. The event-free survival ([Fig. 1](#f0005){ref-type="fig"}) was significantly higher in the low omentin group than in the high omentin group if including all cardiovascular events (EP A, ~pLog-Rank~=0.037), if including all cardiovascular events but excluding revascularization in arterial beds (EP B p~Log-Rank~=0.012), or if including only major cardiovascular events (EP C; ~pLog-Rank~=0.019).

3. Experimental design, materials and methods {#s0015}
=============================================

3.1. Patients {#s0020}
-------------

From a large cohort of 1751 Caucasian patients, who were referred to coronary angiography for the evaluation of established or suspected stable coronary artery disease (CAD), 295 were randomly drawn, except for CAD status (161 had significant CAD and 134 did not have significant CAD) and sex (140 women and 155 men). Patients with acute coronary syndromes were not included. In these 295 patients, we measured plasma omentin. Subsequently, these 295 patients were separated according to the median of measured omentin concentrations into a high omentin group (*n*=147) and a low omentin group (*n*=148). The present study has been approved by the Ethics Committee of the University of Innsbruck; written informed consent was given by all participants.

4. Laboratory analyses {#s0025}
======================

Venous blood samples were collected after an overnight fast of 12 h before angiography was performed and laboratory measurements were performed from fresh plasma samples. Plasma omentin levels were determined with a commercial omentin enzyme-linked immunosorbent assay (ELISA) kit (catalog no. SK00010-01; Aviscera Bioscience, CA, USA) from the same batch of kits (lot no. 20110234), specific for omentin-1 with an inter-assay variation less than 10%. We assessed a mean (+SD) omentin concentration of 17.4 (+14.3) ng/ml and a median of 13.4 (interquartile range 7.9--21.5) ng/ml. Thus the data range is comparable to omentin levels reported for healthy control subjects ranging from 14 to 34 ng/ml [@bib2], [@bib3] and is also in line with other studies [@bib3], [@bib4], [@bib5], [@bib6], [@bib7], [@bib8].

5. Prospective study {#s0030}
====================

Mortality data were collected annually from a national survey (Statistik Austria, Vienna, Austria); follow-up visits to our institution were planned after 3--4 years in order to assess endpoints among survivors. The mean follow up time was 3.5 ±1.1 years after the baseline investigation. To assess non-fatal endpoints we conducted standardized interviews; additionally, hospital records were reviewed.

The data refer to cardiovascular events comprising coronary death (fatal myocardial infarction, sudden cardiac death, mortality from congestive heart failure due to CAD), fatal ischemic stroke, non-fatal myocardial infarction non-fatal ischemic stroke, and need for coronary artery bypass grafting (CABG), percutaneous coronary intervention (PCI), or revascularization in the carotid or peripheral arterial beds. The combination of all these events has been referred to as our primary study endpoint (EP A). Additional endpoints include the composite of coronary death (fatal myocardial infarction, sudden cardiac death, mortality from congestive heart failure due to CAD), fatal ischemic stroke, non-fatal myocardial infarction, non-fatal ischemic stroke, and need for coronary artery bypass grafting (CABG) or percutaneous coronary intervention (PCI) -- i.e. the primary endpoint without revascularization in the carotid or peripheral arterial beds (=EP B); and the composite of coronary death (fatal myocardial infarction, sudden cardiac death, mortality from congestive heart failure due to CAD), fatal ischemic stroke, non-fatal myocardial infarction and non-fatal ischemic stroke -- i.e. major cardiovascular events (=EP C).

Coronary angioplasty and bypass surgery were considered as cardiovascular events unless they were planned as a consequence of the baseline angiography and therefore were not "future" events. A follow-up rate of 95% was achieved.

6. Statistical analysis {#s0035}
=======================

Survival analysis was performed using Kaplan--Meier and Log-Rank tests respectively. Patients who were lost during the follow-up (*n*=15) were not included in the prospective analyses. Statistical analyses were performed with the software package SPSS 22.0 for Macintosh, IBM SPSS; Chicago, IL.

Appendix A. Supplementary material {#s0045}
==================================
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Supplementary data associated with this article can be found in the online version at [doi:10.1016/j.dib.2015.11.065](http://dx.doi.org/10.1016/j.dib.2015.11.065){#ir0005}.

![Incidence of study endpoints by high and low omentin concentration in coronary patients. The survival plot indicates event-free survival according to low (4.0--13.44 ng/ml) and high plasma omentin concentration (13.45--108.3 ng/ml) in angiographied patients during 3.5 years. Study endpoint (EP) A comprise all cardiovascular events, including coronary death, fatal ischemic stroke, non-fatal myocardial infarction, non-fatal ischemic stroke, and need for coronary artery bypass grafting, percutaneous coronary intervention, or revascularization in the carotid or peripheral arterial beds (A). EP B comprises all events of EP A but without revascularization in the carotid or peripheral arterial beds (B). EP C comprises only major cardiovascular events, including coronary death, fatal ischemic stroke, non-fatal myocardial infarction, and non-fatal ischemic stroke (C).](gr1){#f0005}
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